Molecular and In Silico Analysis of the CHEK2 Gene in Individuals with High Risk of Cancer Predisposition from Türkiye
Authors:
- Ozkan OzdemirOOOzkan Ozdemir
- Brittany L. BychkovskyBBBrittany L. Bychkovsky
- Busra UnalBUBusra Unal
- Gizem OnderGOGizem Onder
- Ufuk AmanvermezUAUfuk Amanvermez
- Eylul AydinEAEylul Aydin
- Berk ErgunBEBerk Ergun
- Ilayda SahinISIlayda Sahin
- Merve GokbayrakMGMerve Gokbayrak
- Cansu UgurtasCUCansu Ugurtas
- Merve Nur KorogluMKMerve Nur Koroglu
- Berfin CakirBCBerfin Cakir
Open Access
Abstract
Background and Objectives: Checkpoint kinase 2 (CHEK2) is a tumor suppressor gene involved in DNA repair and cell cycle regulation. Pathogenic or likely pathogenic (P/LP) variants in CHEK2 are associated with increased cancer risk. Conversely, recent large cohort studies have identified certain variants that, despite being classified as P/LP by in silico analysis, are considered low risk. Thus, the genotype–phenotype correlations of CHEK2 require a better understanding. In this study, we aimed to characterize germline CHEK2 variants from a group of individuals who applied to cancer genetic clinics in the Marmara Region of Türkiye. We also aimed to assess the phenotypic impacts of these variants by using a new score of statistically significant in silico predictors (SSIPs). Methods: We analyzed 1707 individuals with high risk cancer predisposition, focusing on germline CHEK2 variants, using SSIP scores and population-specific data. Results:CHEK2 variants appeared in approximately 8% of cases. The SSIP scores indicated that the missense mutation, p.Arg117Gly, significantly impairs DNA repair. Almost half of the variants had higher allele frequencies than the variants listed in the Genome Aggregation Database (gnomAD), and three variants had significantly higher frequencies compared to the variants listed on the Turkish Variome database (p.Thr476Met, p.Arg137Gln, c.592+3A>T), emphasizing the importance of population-specific data. Conclusions: This comprehensive analysis of CHEK2 variants in the Turkish population provides crucial insights for cancer geneticists and oncologists. Our findings will help to enhance the evaluation and management of cancer predisposition associated with CHEK2 in Türkiye and other regions that have significant Turkish populations.Keywords
Funding Information
- the framework of the 2219—International Postdoctoral Research Scholarship Program provided by TUBITAK BİDEB (1059B192100905, 118C082)
- TÜBİTAK-BIDEB 2244 Industrial Ph.D. Program (1059B192100905, 118C082)
This publication has 31 references indexed in Scilit:
- Cancer burden in individuals with single versus double pathogenic variants in cancer susceptibility genesGenetics in Medicine Open, 2024
- Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: A comparison of missense versus truncating variantsCancer Genetics, 2023
- Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)Genetics in Medicine, 2023
- DALI shines a light on remote homologs: One hundred discoveriesProtein Science, 2022
- Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2JAMA Oncology, 2022
- Comparison of Pathogenicity Prediction Tools on Somatic VariantsThe Journal of Molecular Diagnostics, 2020
- Overview of Specifications to the ACMG/AMP Variant Interpretation GuidelinesCurrent Protocols in Human Genetics, 2019
- CHEK2 c.1100delC allele is rarely identified in Greek breast cancer casesCancer Genetics, 2015
- Absence of CHEK2 mutations in Spanish families with hereditary breast cancerCancer Genetics and Cytogenetics, 2005
- The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in ItalyHuman Mutation, 2004